Search

Your search keyword '"Papp, Andras"' showing total 116 results

Search Constraints

Start Over You searched for: Author "Papp, Andras" Remove constraint Author: "Papp, Andras"
116 results on '"Papp, Andras"'

Search Results

1. Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials

3. Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial

4. Efficacy and Safety of Ranibizumab Biosimilar QL1205 in Neovascular Age-Related Macular Degeneration: A Phase III Randomized Trial

5. Biosimilar Candidate CT-P42 in Diabetic Macular Edema: 24-Week Results from a Randomized, Active-Controlled, Phase III Study

6. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial

7. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials

8. Faricimab Treat-and-Extend for Diabetic Macular Edema

9. Vision-Related Quality of Life in Patients with Diabetic Macular Edema Treated with Intravitreal Aflibercept: The AQUA Study

10. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial

16. DElayed COloRectal cancer care during COVID-19 Pandemic (DECOR-19): Global perspective from an international survey

19. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials

21. Folate Supplementation in Rats: Does it Cause Behavioural and Electrophysiological Changes?

26. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials

27. Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration

29. Prevalence of Cilioretinal Arteries: A systematic review and a prospective cross‐sectional observational study

39. Vision-Related Quality of Life in Patients with Diabetic Macular Edema Treated with Intravitreal Aflibercept

40. Prevalence of Cilioretinal Arteries: A systematic review and a prospective cross‐sectional observational study.

41. Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.

45. Achalasia following reflux disease: coincidence, consequence, or accommodation? An experience-based literature review

48. The SECURE study: long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degeneration

49. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial

Catalog

Books, media, physical & digital resources